CJC-1295: Research Overview

The short version

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH), engineered to last days in circulation rather than minutes. A 2006 human pharmacology study found a single dose raised growth hormone 2- to 10-fold and IGF-1 1.5- to 3-fold in healthy adults, with effects lasting 6–11 days ^[11]. Another 2006 study confirmed that normal pulsatile GH secretion is preserved — not overridden — during sustained GHRH stimulation ^[12].

CJC-1295 was never approved by any regulator. The DAC (Drug Affinity Complex) development program was discontinued; the FDA's 2024 Pharmacy Compounding Advisory Committee did not recommend it for the 503A compounding list, citing immunogenicity and other safety concerns ^[8]. It is prohibited in sport at all times under WADA Section S2. Published human evidence is limited to early pharmacology studies; no long-term safety or efficacy trials were completed. No dosing advice appears on this page.

What it is

CJC-1295 is built on the first 29 residues of human GRF (hGRF(1-29)) with four protective amino-acid substitutions at positions 2, 8, 15, and 27 that block degradation and stabilize the alpha-helix. In the DAC variant (Drug Affinity Complex), a C-terminal lysine carries a maleimidopropionyl linker that undergoes Michael addition with the free thiol on Cys34 of circulating serum albumin — creating a covalent peptide-albumin conjugate with an estimated plasma half-life of 5.8–8.1 days ^[11]. The no-DAC variant (often called Modified GRF 1-29) retains the four stabilizing substitutions but lacks the albumin linker, so it remains short-acting (minutes to hours).

The two variants are pharmacokinetically very different and are routinely conflated in community discussion ^[8]. LC-MS/MS analysis of a seized preparation confirmed CJC-1295 is identifiable as the active ingredient in gray-market GHRH products ^[9].

How it works

CJC-1295 binds the GHRH receptor (GHRHR) on anterior-pituitary somatotrophs, activating Gs/cAMP/PKA signaling that drives synthesis and release of growth hormone ^[8]. Because GH release from the pituitary is pulsatile by nature, and because CJC-1295 stimulates release without locking the pituitary into continuous output, the pulsatile GH pattern is preserved during sustained GHRH stimulation ^[12]. Elevated GH signals the liver to produce more IGF-1, which is the downstream mediator of many growth and repair effects associated with GH-axis activation.

The DAC albumin-binding design mirrors the strategy used for other long-acting peptide drugs: piggybacking on the long half-life of serum albumin (~19 days) to extend the peptide's own circulating lifetime ^[8]. This also means that once the DAC variant is injected, its GH and IGF-1 effects persist for days whether or not that was the intent.

What the research shows

The human pharmacology picture is real but limited:

• A 2006 dose-escalation trial in healthy adults (ages 21–61) found single subcutaneous doses of 30 or 60 micrograms/kg raised mean GH 2- to 10-fold for 6 days or longer, and IGF-1 by 1.5- to 3-fold for 9–11 days. After multiple doses, IGF-1 remained above baseline for up to 28 days. The estimated half-life was 5.8–8.1 days ^[11].
• A separate 2006 study in healthy men ages 20–40 found basal GH rose approximately 7.5-fold and mean GH by ~46%, with IGF-1 up ~45% one week after a single dose. Pulsatile GH secretion frequency and magnitude were unchanged ^[12].
• An 11-subject serum-proteomics study documented CJC-1295-driven shifts in the serum protein profile — decreased apolipoprotein A1, increased albumin-fragment and immunoglobulin species — that correlated linearly with IGF-1, identifying candidate biomarkers of GH/IGF-1 axis activation ^[10].
• An authoritative 2025 Nature Reviews Endocrinology review places CJC-1295 within the GHRH-analog class, covering receptor signaling, long-acting design rationale, and the investigational landscape ^[8].

No approved-indication efficacy trial for CJC-1295 was published. The DAC program's Phase 2 trial in HIV-associated visceral obesity was discontinued.

Reported effects, cautions, and safety

What people in research-use communities report (anecdotal, not clinical evidence): The most commonly reported benefit is deeper, more restful sleep — consistent with the biology of GH, which is released predominantly during slow-wave sleep. Faster recovery from training and gradual fat loss around the midsection are also frequently reported. Less common are reports of improved focus, firmer skin feel, and increased daytime energy. The most common adverse effects reported anecdotally are water retention and puffiness (especially with the long-acting DAC form), tingling or numbness in the hands (carpal-tunnel-like, attributed to fluid retention), injection-site reactions, and occasional flushing or brief head-rush. Increased appetite, fatigue, and mild blood-sugar shifts have been reported less often.

Safety cautions from the published literature and regulatory record:

• Never approved for human use; sold only as a research chemical.
• The FDA cited immunogenicity as a concern when reviewing CJC-1295 for the 503A compounding bulks list in 2024 ^[8].
• Sustained IGF-1 elevation: epidemiological data associate higher IGF-1 with modestly increased risk of certain cancers; the mechanism-based concern is real for long-duration use.
• Growth hormone is glucose-sparing; sustained GH axis stimulation can reduce insulin sensitivity and raise blood sugar — a documented concern with GHRH analogs.
• Fluid retention from GH-driven sodium/water retention can cause real discomfort and nerve-compression symptoms.
• DAC and no-DAC variants behave very differently — the long-acting form drives more sustained physiological effects and the attendant risks; knowing which form is being used is essential.
• WADA status: Prohibited at all times under Section S2 (Peptide Hormones, Growth Factors, Related Substances).

Where it fits in the research landscape

CJC-1295 occupies the growth-hormone axis on this desk — distinct from BPC-157's repair/angiogenesis focus, GHK-Cu's matrix biology, and Retatrutide's metabolic triple-agonism. It shares the GH-axis space with sermorelin (the shorter-acting predecessor, once briefly approved and now a 503A category-1 compounding candidate) and tesamorelin (FDA-approved for a specific HIV-related condition only). CJC-1295 itself reached neither approval nor a published efficacy trial, leaving it with a solid pharmacology profile and an open clinical question.